{"transactions":[{"id":2334928,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-14T20:56:19.000Z","date":"2022-03-10","kind":"sale","acquired":false,"shares":12823,"price":15.5451,"value":199334.8173,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":201883,"source":{"system":"sec-edgar","filing":"0001209191-22-018509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122018509/doc4.xml","form_type":"4"}},{"id":2352912,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2022-03-03T23:08:11.000Z","date":"2022-03-02","kind":"exercise","acquired":false,"shares":8297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":16595,"derivative":{"underlying":"Common Stock","underlying_shares":8297},"source":{"system":"sec-edgar","filing":"0001209191-22-015809","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122015809/doc4.xml","form_type":"4"}},{"id":2352911,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2022-03-03T23:08:11.000Z","date":"2022-03-01","kind":"exercise","acquired":false,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":24900,"derivative":{"underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001209191-22-015809","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122015809/doc4.xml","form_type":"4"}},{"id":2352910,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2022-03-03T23:08:11.000Z","date":"2022-03-01","kind":"exercise","acquired":false,"shares":25750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":25750,"derivative":{"underlying":"Common Stock","underlying_shares":25750},"source":{"system":"sec-edgar","filing":"0001209191-22-015809","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122015809/doc4.xml","form_type":"4"}},{"id":2352909,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2022-03-03T23:08:11.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":44300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date."}],"balance_after":44300,"derivative":{"underlying":"Common Stock","underlying_shares":44300},"source":{"system":"sec-edgar","filing":"0001209191-22-015809","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122015809/doc4.xml","form_type":"4"}},{"id":2352908,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-03-03T23:08:11.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":155200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date."}],"balance_after":155200,"derivative":{"exercise_price":14.94,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":155200},"source":{"system":"sec-edgar","filing":"0001209191-22-015809","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122015809/doc4.xml","form_type":"4"}},{"id":2352907,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:08:11.000Z","date":"2022-03-02","kind":"exercise","acquired":true,"shares":8297,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":214706,"source":{"system":"sec-edgar","filing":"0001209191-22-015809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122015809/doc4.xml","form_type":"4"}},{"id":2352906,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:08:11.000Z","date":"2022-03-01","kind":"exercise","acquired":true,"shares":8300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":206409,"source":{"system":"sec-edgar","filing":"0001209191-22-015809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122015809/doc4.xml","form_type":"4"}},{"id":2352905,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:08:11.000Z","date":"2022-03-01","kind":"exercise","acquired":true,"shares":25750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":198109,"source":{"system":"sec-edgar","filing":"0001209191-22-015809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122015809/doc4.xml","form_type":"4"}},{"id":2401077,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-11T21:18:56.000Z","date":"2022-02-09","kind":"sale","acquired":false,"shares":1388,"price":12.6574,"value":17568.4712,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2022 pursuant to preexisting sell-to-cover elections."}],"balance_after":172359,"source":{"system":"sec-edgar","filing":"0001209191-22-008849","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122008849/doc4.xml","form_type":"4"}},{"id":2413017,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-03T21:46:40.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":3875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vested on February 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vested on February 1, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3875},"source":{"system":"sec-edgar","filing":"0001209191-22-006832","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122006832/doc4.xml","form_type":"4"}},{"id":2413016,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-03T21:46:40.000Z","date":"2022-02-01","kind":"exercise","acquired":true,"shares":3875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":173747,"source":{"system":"sec-edgar","filing":"0001209191-22-006832","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122006832/doc4.xml","form_type":"4"}},{"id":2685873,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-06-03T01:43:35.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":33189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":33189},"source":{"system":"sec-edgar","filing":"0001209191-21-037475","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121037475/doc4.xml","form_type":"4"}},{"id":2685872,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:43:35.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":2450,"price":22.3,"value":54635.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.06 to $22.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":169872,"source":{"system":"sec-edgar","filing":"0001209191-21-037475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121037475/doc4.xml","form_type":"4"}},{"id":2685871,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:43:35.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":12587,"price":21.5101,"value":270747.6287,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.06 to $22.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":172322,"source":{"system":"sec-edgar","filing":"0001209191-21-037475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121037475/doc4.xml","form_type":"4"}},{"id":2685870,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:43:35.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":33189,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":184909,"source":{"system":"sec-edgar","filing":"0001209191-21-037475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121037475/doc4.xml","form_type":"4"}},{"id":2739348,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-27T01:45:19.000Z","date":"2021-04-26","kind":"sale","acquired":false,"shares":100,"price":26.44,"value":2644.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."}],"balance_after":151720,"source":{"system":"sec-edgar","filing":"0001209191-21-028453","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121028453/doc4.xml","form_type":"4"}},{"id":2739347,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-27T01:45:19.000Z","date":"2021-04-26","kind":"sale","acquired":false,"shares":27239,"price":25.7933,"value":702583.6987,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.38 to $26.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":151820,"source":{"system":"sec-edgar","filing":"0001209191-21-028453","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121028453/doc4.xml","form_type":"4"}},{"id":2739346,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-27T01:45:19.000Z","date":"2021-04-23","kind":"sale","acquired":false,"shares":800,"price":27.3287,"value":21862.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.23 to $27.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":179059,"source":{"system":"sec-edgar","filing":"0001209191-21-028453","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121028453/doc4.xml","form_type":"4"}},{"id":2739345,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-27T01:45:19.000Z","date":"2021-04-23","kind":"sale","acquired":false,"shares":29200,"price":26.6369,"value":777797.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.23 to $27.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":179859,"source":{"system":"sec-edgar","filing":"0001209191-21-028453","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121028453/doc4.xml","form_type":"4"}},{"id":2739344,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-27T01:45:19.000Z","date":"2021-04-22","kind":"sale","acquired":false,"shares":30000,"price":26.8406,"value":805218.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.51 to $27.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":209059,"source":{"system":"sec-edgar","filing":"0001209191-21-028453","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121028453/doc4.xml","form_type":"4"}},{"id":2811546,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2021-03-04T01:36:09.000Z","date":"2021-03-02","kind":"exercise","acquired":false,"shares":8297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":24892,"derivative":{"underlying":"Common Stock","underlying_shares":8297},"source":{"system":"sec-edgar","filing":"0001209191-21-017533","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017533/doc4.xml","form_type":"4"}},{"id":2811545,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2021-03-04T01:36:09.000Z","date":"2021-03-01","kind":"exercise","acquired":false,"shares":25750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":51500,"derivative":{"underlying":"Common Stock","underlying_shares":25750},"source":{"system":"sec-edgar","filing":"0001209191-21-017533","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017533/doc4.xml","form_type":"4"}},{"id":2811544,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2021-03-04T01:36:09.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":33200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":33200,"derivative":{"underlying":"Common Stock","underlying_shares":33200},"source":{"system":"sec-edgar","filing":"0001209191-21-017533","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017533/doc4.xml","form_type":"4"}},{"id":2811543,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-04T01:36:09.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":116000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date."}],"balance_after":116000,"derivative":{"exercise_price":24.06,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":116000},"source":{"system":"sec-edgar","filing":"0001209191-21-017533","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017533/doc4.xml","form_type":"4"}},{"id":2811542,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:36:09.000Z","date":"2021-03-02","kind":"tax_withholding","acquired":false,"shares":2844,"price":23.25,"value":66123.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":239059,"source":{"system":"sec-edgar","filing":"0001209191-21-017533","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017533/doc4.xml","form_type":"4"}},{"id":2811541,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:36:09.000Z","date":"2021-03-02","kind":"exercise","acquired":true,"shares":8297,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":241903,"source":{"system":"sec-edgar","filing":"0001209191-21-017533","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017533/doc4.xml","form_type":"4"}},{"id":2811540,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:36:09.000Z","date":"2021-03-01","kind":"tax_withholding","acquired":false,"shares":7333,"price":24.06,"value":176431.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":233606,"source":{"system":"sec-edgar","filing":"0001209191-21-017533","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017533/doc4.xml","form_type":"4"}},{"id":2811539,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:36:09.000Z","date":"2021-03-01","kind":"exercise","acquired":true,"shares":25750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":240939,"source":{"system":"sec-edgar","filing":"0001209191-21-017533","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017533/doc4.xml","form_type":"4"}},{"id":2880823,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-03T22:29:24.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":3875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":3875,"derivative":{"underlying":"Common Stock","underlying_shares":3875},"source":{"system":"sec-edgar","filing":"0001209191-21-007375","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121007375/doc4.xml","form_type":"4"}},{"id":2880822,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T22:29:24.000Z","date":"2021-02-01","kind":"tax_withholding","acquired":false,"shares":1308,"price":21.35,"value":27925.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":215189,"source":{"system":"sec-edgar","filing":"0001209191-21-007375","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121007375/doc4.xml","form_type":"4"}},{"id":2880821,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T22:29:24.000Z","date":"2021-02-01","kind":"exercise","acquired":true,"shares":3875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":216497,"source":{"system":"sec-edgar","filing":"0001209191-21-007375","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121007375/doc4.xml","form_type":"4"}},{"id":2939405,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-12-17T22:07:27.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001209191-20-064126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120064126/doc4.xml","form_type":"4"}},{"id":2939404,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-17T22:07:27.000Z","date":"2020-12-15","kind":"tax_withholding","acquired":false,"shares":370,"price":4.59,"value":1698.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":212622,"source":{"system":"sec-edgar","filing":"0001209191-20-064126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120064126/doc4.xml","form_type":"4"}},{"id":2939403,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-17T22:07:27.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":1300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":212992,"source":{"system":"sec-edgar","filing":"0001209191-20-064126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120064126/doc4.xml","form_type":"4"}},{"id":3123235,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2020-06-03T20:45:47.000Z","date":"2020-06-01","kind":"exercise","acquired":false,"shares":33188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":33189,"derivative":{"underlying":"Common Stock","underlying_shares":33188},"source":{"system":"sec-edgar","filing":"0001209191-20-034068","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120034068/doc4.xml","form_type":"4"}},{"id":3123234,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-03T20:45:47.000Z","date":"2020-06-01","kind":"tax_withholding","acquired":false,"shares":9451,"price":1.32,"value":12475.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":211692,"source":{"system":"sec-edgar","filing":"0001209191-20-034068","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120034068/doc4.xml","form_type":"4"}},{"id":3123233,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-03T20:45:47.000Z","date":"2020-06-01","kind":"exercise","acquired":true,"shares":33188,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":221143,"source":{"system":"sec-edgar","filing":"0001209191-20-034068","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120034068/doc4.xml","form_type":"4"}},{"id":3226478,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2020-03-04T21:30:00.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":33189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":33189,"derivative":{"underlying":"Common Stock","underlying_shares":33189},"source":{"system":"sec-edgar","filing":"0001209191-20-016092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016092/doc4.xml","form_type":"4"}},{"id":3226477,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2020-03-04T21:30:00.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":66377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":66377,"derivative":{"underlying":"Common Stock","underlying_shares":66377},"source":{"system":"sec-edgar","filing":"0001209191-20-016092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016092/doc4.xml","form_type":"4"}},{"id":3226476,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-04T21:30:00.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":116160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date."}],"balance_after":116160,"derivative":{"exercise_price":1.26,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":116160},"source":{"system":"sec-edgar","filing":"0001209191-20-016092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016092/doc4.xml","form_type":"4"}},{"id":3226475,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2020-03-04T21:30:00.000Z","date":"2020-03-02","kind":"exercise","acquired":false,"shares":25750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":77250,"derivative":{"underlying":"Common Stock","underlying_shares":25750},"source":{"system":"sec-edgar","filing":"0001209191-20-016092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016092/doc4.xml","form_type":"4"}},{"id":3226474,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-04T21:30:00.000Z","date":"2020-03-02","kind":"tax_withholding","acquired":false,"shares":7162,"price":1.26,"value":9024.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":187955,"source":{"system":"sec-edgar","filing":"0001209191-20-016092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016092/doc4.xml","form_type":"4"}},{"id":3226473,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-04T21:30:00.000Z","date":"2020-03-02","kind":"exercise","acquired":true,"shares":25750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":195117,"source":{"system":"sec-edgar","filing":"0001209191-20-016092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016092/doc4.xml","form_type":"4"}},{"id":3290619,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-05T00:12:07.000Z","date":"2020-02-03","kind":"exercise","acquired":false,"shares":3875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":7750,"derivative":{"underlying":"Common Stock","underlying_shares":3875},"source":{"system":"sec-edgar","filing":"0001209191-20-006667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120006667/doc4.xml","form_type":"4"}},{"id":3290618,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-05T00:12:07.000Z","date":"2020-02-03","kind":"tax_withholding","acquired":false,"shares":1308,"price":1.28,"value":1674.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":169367,"source":{"system":"sec-edgar","filing":"0001209191-20-006667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120006667/doc4.xml","form_type":"4"}},{"id":3290617,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-05T00:12:07.000Z","date":"2020-02-03","kind":"exercise","acquired":true,"shares":3875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":170675,"source":{"system":"sec-edgar","filing":"0001209191-20-006667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120006667/doc4.xml","form_type":"4"}},{"id":3333611,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-12-20T21:18:46.000Z","date":"2019-12-18","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001209191-19-061540","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119061540/doc4.xml","form_type":"4"}},{"id":3333610,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-12-20T21:18:46.000Z","date":"2019-12-18","kind":"tax_withholding","acquired":false,"shares":356,"price":1.81,"value":644.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":166800,"source":{"system":"sec-edgar","filing":"0001209191-19-061540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119061540/doc4.xml","form_type":"4"}},{"id":3333609,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-12-20T21:18:46.000Z","date":"2019-12-18","kind":"exercise","acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":167156,"source":{"system":"sec-edgar","filing":"0001209191-19-061540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119061540/doc4.xml","form_type":"4"}},{"id":3336302,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-12-18T16:02:40.000Z","date":"2019-12-16","kind":"exercise","acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":1300,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001209191-19-061068","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119061068/doc4.xml","form_type":"4"}},{"id":3336301,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-12-18T16:02:40.000Z","date":"2019-12-16","kind":"tax_withholding","acquired":false,"shares":370,"price":1.8,"value":666.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":165906,"source":{"system":"sec-edgar","filing":"0001209191-19-061068","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119061068/doc4.xml","form_type":"4"}},{"id":3336300,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-12-18T16:02:40.000Z","date":"2019-12-16","kind":"exercise","acquired":true,"shares":1300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":166276,"source":{"system":"sec-edgar","filing":"0001209191-19-061068","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119061068/doc4.xml","form_type":"4"}},{"id":3617871,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2019-03-04T23:11:22.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":103000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":103000,"derivative":{"underlying":"Common Stock","underlying_shares":103000},"source":{"system":"sec-edgar","filing":"0001209191-19-015892","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119015892/doc4.xml","form_type":"4"}},{"id":3673590,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-05T23:31:39.000Z","date":"2019-02-01","kind":"exercise","acquired":false,"shares":3875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":11625,"derivative":{"underlying":"Common Stock","underlying_shares":3875},"source":{"system":"sec-edgar","filing":"0001209191-19-007487","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119007487/doc4.xml","form_type":"4"}},{"id":3673589,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-05T23:31:39.000Z","date":"2019-02-01","kind":"tax_withholding","acquired":false,"shares":1308,"price":6.96,"value":9103.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":164976,"source":{"system":"sec-edgar","filing":"0001209191-19-007487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119007487/doc4.xml","form_type":"4"}},{"id":3673588,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-05T23:31:39.000Z","date":"2019-02-01","kind":"exercise","acquired":true,"shares":3875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":166284,"source":{"system":"sec-edgar","filing":"0001209191-19-007487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119007487/doc4.xml","form_type":"4"}},{"id":3720575,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-12-21T12:34:35.000Z","date":"2018-12-18","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":1250,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001209191-18-063805","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118063805/doc4.xml","form_type":"4"}},{"id":3720574,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:34:35.000Z","date":"2018-12-18","kind":"tax_withholding","acquired":false,"shares":356,"price":6.3,"value":2242.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":162409,"source":{"system":"sec-edgar","filing":"0001209191-18-063805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118063805/doc4.xml","form_type":"4"}},{"id":3720573,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-21T12:34:35.000Z","date":"2018-12-18","kind":"exercise","acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":162765,"source":{"system":"sec-edgar","filing":"0001209191-18-063805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118063805/doc4.xml","form_type":"4"}},{"id":3726265,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-12-19T01:54:01.000Z","date":"2018-12-15","kind":"exercise","acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":2600,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001209191-18-063372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118063372/doc4.xml","form_type":"4"}},{"id":3726264,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-19T01:54:01.000Z","date":"2018-12-15","kind":"tax_withholding","acquired":false,"shares":370,"price":7.31,"value":2704.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":161515,"source":{"system":"sec-edgar","filing":"0001209191-18-063372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118063372/doc4.xml","form_type":"4"}},{"id":3726263,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-19T01:54:01.000Z","date":"2018-12-15","kind":"exercise","acquired":true,"shares":1300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":161885,"source":{"system":"sec-edgar","filing":"0001209191-18-063372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118063372/doc4.xml","form_type":"4"}},{"id":3940541,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-05-09T20:20:34.000Z","date":"2018-05-07","kind":"exercise","acquired":false,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units.  50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone.  The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units.  50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone.  The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":3900,"derivative":{"underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001209191-18-028860","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118028860/doc4.xml","form_type":"4"}},{"id":3940540,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-05-09T20:20:34.000Z","date":"2018-05-07","kind":"tax_withholding","acquired":false,"shares":1480,"price":18.1,"value":26788.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":160585,"source":{"system":"sec-edgar","filing":"0001209191-18-028860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118028860/doc4.xml","form_type":"4"}},{"id":3940539,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-05-09T20:20:34.000Z","date":"2018-05-07","kind":"exercise","acquired":true,"shares":5200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":162065,"source":{"system":"sec-edgar","filing":"0001209191-18-028860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118028860/doc4.xml","form_type":"4"}},{"id":3943975,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-05-07T20:28:03.000Z","date":"2018-05-07","kind":"purchase","acquired":true,"shares":1250,"price":18.22,"value":22775.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $18.22 to $18.28, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":156865,"source":{"system":"sec-edgar","filing":"0001209191-18-028324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118028324/doc4.xml","form_type":"4"}},{"id":3966821,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-04-09T20:51:51.000Z","date":"2018-04-06","kind":"purchase","acquired":true,"shares":1250,"price":16.59,"value":20737.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.33 to $17.01, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":155615,"source":{"system":"sec-edgar","filing":"0001209191-18-024357","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118024357/doc4.xml","form_type":"4"}},{"id":3987275,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-20T21:00:53.000Z","date":"2018-03-16","kind":"other","acquired":true,"shares":9018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from NST, LLC, of which the reporting person is a non-managing member, in accordance with NST, LLC's Limited Liability Company Operating Agreement."}],"balance_after":154365,"source":{"system":"sec-edgar","filing":"0001209191-18-020917","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118020917/doc4.xml","form_type":"4"}},{"id":4075661,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2018-02-05T21:21:42.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":15500,"derivative":{"underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-18-007468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118007468/doc4.xml","form_type":"4"}},{"id":4075660,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-02-05T21:21:42.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":54000,"derivative":{"exercise_price":22.09,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":54000},"source":{"system":"sec-edgar","filing":"0001209191-18-007468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118007468/doc4.xml","form_type":"4"}},{"id":4123298,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-12-21T21:57:44.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":2500,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001209191-17-066820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117066820/doc4.xml","form_type":"4"}},{"id":4123297,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-12-21T21:57:44.000Z","date":"2017-12-15","kind":"exercise","acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units, with 50% of the shares underlying the restricted stock units vesting in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units vesting upon the achievement of a specified commercial milestone, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 10,400 restricted stock units, with 50% of the shares underlying the restricted stock units vesting in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units vesting upon the achievement of a specified commercial milestone, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":9100,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001209191-17-066820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117066820/doc4.xml","form_type":"4"}},{"id":4123296,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-12-21T21:57:44.000Z","date":"2017-12-18","kind":"tax_withholding","acquired":false,"shares":380,"price":24.12,"value":9165.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":145347,"source":{"system":"sec-edgar","filing":"0001209191-17-066820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117066820/doc4.xml","form_type":"4"}},{"id":4123295,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-12-21T21:57:44.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":145727,"source":{"system":"sec-edgar","filing":"0001209191-17-066820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117066820/doc4.xml","form_type":"4"}},{"id":4123294,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-12-21T21:57:44.000Z","date":"2017-12-15","kind":"tax_withholding","acquired":false,"shares":395,"price":24.23,"value":9570.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":144477,"source":{"system":"sec-edgar","filing":"0001209191-17-066820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117066820/doc4.xml","form_type":"4"}},{"id":4123293,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-12-21T21:57:44.000Z","date":"2017-12-15","kind":"exercise","acquired":true,"shares":1300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":144872,"source":{"system":"sec-edgar","filing":"0001209191-17-066820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117066820/doc4.xml","form_type":"4"}},{"id":4515086,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2016-12-20T23:51:01.000Z","date":"2016-12-18","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":3750,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001209191-16-156177","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919116156177/doc4.xml","form_type":"4"}},{"id":4515085,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-12-20T23:51:01.000Z","date":"2016-12-18","kind":"tax_withholding","acquired":false,"shares":380,"price":31.25,"value":11875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":143572,"source":{"system":"sec-edgar","filing":"0001209191-16-156177","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919116156177/doc4.xml","form_type":"4"}},{"id":4515084,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-12-20T23:51:01.000Z","date":"2016-12-18","kind":"exercise","acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":143952,"source":{"system":"sec-edgar","filing":"0001209191-16-156177","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919116156177/doc4.xml","form_type":"4"}},{"id":4516635,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2016-12-19T22:22:13.000Z","date":"2016-12-15","kind":"grant","acquired":true,"shares":10400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone."}],"balance_after":10400,"derivative":{"underlying":"Common Stock","underlying_shares":10400},"source":{"system":"sec-edgar","filing":"0001209191-16-155968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919116155968/doc4.xml","form_type":"4"}},{"id":4516634,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2016-12-19T22:22:13.000Z","date":"2016-12-15","kind":"grant","acquired":true,"shares":62400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":62400,"derivative":{"exercise_price":28.92,"expiration_date":"2026-12-14","underlying":"Common Stock","underlying_shares":62400},"source":{"system":"sec-edgar","filing":"0001209191-16-155968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919116155968/doc4.xml","form_type":"4"}},{"id":4599644,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":129141,"kind":"person","name":"Ruffo Frank","position":1,"cik":"0001654450","reported_name":"Ruffo Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-09-19T23:07:00.000Z","date":"2016-09-15","kind":"other","acquired":true,"shares":4790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from NST, LLC, of which the reporting person is a non-managing member, in accordance with NST, LLC's Limited Liability Company Operating Agreement."}],"balance_after":142702,"source":{"system":"sec-edgar","filing":"0001209191-16-142069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919116142069/doc4.xml","form_type":"4"}}]}